================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): JUNE 6, 2003
SHEFFIELD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
1-12584 13-3808303
(Commission File Number) (I.R.S. Employer Identification No.)
3136 WINTON ROAD, SUITE 201, ROCHESTER, NEW YORK 14623
(Address of principal executive offices) (Zip Code)
(585) 292-0310
(Company's telephone number, including area code)
(NOT APPLICABLE)
(Former name or former address, if changed since last report)
================================================================================
ITEM 3. BANKRUPTCY OR RECEIVERSHIP
On June 6, 2003, Sheffield Pharmaceuticals, Inc. announced that it has ceased
operations and filed a bankruptcy petition under Chapter 7 of the United States
Bankruptcy Code. The petition was filed on June 6, 2003 with the United States
Bankruptcy Court for the Western District of New York.
As a result of the initiation of bankruptcy proceedings, Sheffield
Pharmaceuticals, Inc. expects that it will cease filing periodic reports under
the Securities Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SHEFFIELD PHARMACEUTICALS, INC.
June 6, 2003 By: /s/ Thomas M. Fitzgerald
-----------------------------------------
Thomas M. Fitzgerald
President and Chief Executive Officer